Clinical Trial Search

Primary: Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 12 — 30.1; 9.4 percent change — p=<0.001

Primary: Percentage of Participants Experiencing at Least a 1-grade Increase on the Global Eyelash Assessment (GEA) Scale From Baseline to Week 16 — 5.1; 2.1; 14.6; 7.8…

Primary: Percent Change in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 8 During 10 mg Atorvastatin Treatment Period — -40.2; -33.7 percent change…

Primary: Safety and Tolerability of a Single-dose of Famciclovir in Part A of the Study. — 0; 2; 1; 2 participants

Primary: Composite Major Adverse Event (MAE) Rate — 0; 5; 2; 2 participants — p=0.002

Primary: Number of Subjects Reporting Any Serious Adverse Events (SAEs). — 34; 23 subjects

Primary: Change From Baseline in HbA1c (Hemoglobin A1c) at Week 24 — -0.47; 0.23 Percent — p=<0.001

Primary: Death — 27; 22 participants

Primary: Number of Responders With Carbon Monoxide (CO) Confirmed 4-week Continuous Quit Rate (CQR) for Last 4 Weeks of Treatment (Trtmt) — 167; 50; 186; 300 participants…

Primary: Change From Baseline Hair Growth Assessed by Macrophotographic Technique (Hair Count) in the Vertex at 6 Months. — 148.14; 144.27; 162.27; 149.57 hair count per…

Primary: Change in Mean Trough Sitting Diastolic Blood Pressure — -11.16; -10.45 mm Hg — p=0.2648

Primary: Exercise Capacity — 465.5; 462.7 meters — p=<0.05

Primary: Percentage of Patients With Testosterone <=0.5ng/mL From Day 28 Through Day 364 — 98.3; 97.2; 96.4 percentage of patients

Primary: Change in Blood Phenylalanine Levels From Baseline to Week 6. — 843; 888; 607; 891 micromole per liter — p=<0.001

Primary: Total Dose of Zemuron (Rocuronium) Administered — 0.91; 0.78; 0.86; 0.81 mg/kg